Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Home
Hostname: page-component-ffbbcc459-kf4bb Total loading time: 0.722 Render date: 2022-03-13T20:30:28.876Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "useRatesEcommerce": false, "useNewApi": true }
  • English
CNS Spectrums CNS Spectrums

Article contents

Improving the Prediction of Treatment Response in Depression: Integration of Clinical, Cognitive, Psychophysiological, Neuroimaging, and Genetic Measures

Published online by Cambridge University Press:  07 November 2014

Andrew H. Kemp ,
Evian Gordon ,
A. John Rush  and
Leanne M. Williams
Get access Rights & Permissions[Opens in a new window]

Abstract

Antidepressants are important in the treatment of depression, and selective serotonin reuptake inhibitors are first-line pharmacologic options. However, only 50% to 70% of patients respond to first treatment and <40% remit. Since depression is associated with substantial morbidity, mortality, and family burden, it is unfortunate and demanding on health resources that patients must remain on their prescribed medications for at least 4 weeks without knowing whether the particular antidepressant will be effective. Studies have suggested a number of predictors of treatment response, including clinical, psychophysiological, neuroimaging, and genetics, each with varying degrees of success and nearly all with poor prognostic sensitivity and specificity. Studies are yet to be conducted that use multiple measures from these different domains to determine whether sensitivity and specificity can be improved to predict individual treatment response. It is proposed that a focus on standardized testing methodologies across multiple testing modalities and their integration will be crucial for translation of research findings into clinical practice.

Type
Review Articles
Information
CNS Spectrums , Volume 13 , Issue 12 , December 2008 , pp. 1066 - 1086
Copyright
Copyright © Cambridge University Press 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Diagnostic and Statistical Manual of Mental Disorders. 4th ed, text rev. Washington, DC: American Psychiatric Association; 2000.Google Scholar
2.Judd, LL, Akiskal, HS, Zeller, PJ, et al.Psychosocial disability during the long-term course of unipolar major depressive disorder. Arch Gen Psychiatry. 2000;57:375–380.CrossRefGoogle ScholarPubMed
3.Murray, C, Lopez, A. Global Health Statistics: A Compendium of Incidence, Prevalence and Mortality Estimates for Over 2000 Conditions. Available at: www.popline.org/docs/1203/253379.html. Accessed November 6, 2008.Google Scholar
4.Gartlehner, G, Hansen, RA, Thieda, P, et al. Comparative effectiveness of second-generation antidepressants in the pharmacologic treatment of adult depression. Comparative effectiveness review no. 7. Available at: http://effectivehealthcare.ahrq.gov/healthInfo.cfm?infotype=rr&ProcessID=7&DocID=61. Accessed November 6, 2008.Google Scholar
5.Kornstein, SG, Schneider, RK. Clinical features of treatment-resistant depression. J Clin Psychiatry. 2001;62:18–25.Google ScholarPubMed
6.Berrettini, W. Psychiatric pharmacogenetics: a developing science. Neuropsychopharmacology. 2002;26:128–129.Google ScholarPubMed
7.Trivedi, MH, Rush, AJ, Wisniewski, SR, et al.Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163:28–40.CrossRefGoogle ScholarPubMed
8.Kirsch, I, Deacon, BJ, Huedo-Medina, TB, Scoboria, A, Moore, TJ, Johnson, BT. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med. 2008;5:e45.CrossRefGoogle ScholarPubMed
9.Parker, G. Classifying depression: should paradigms lost be regained? Am J Psychiatry. 2000;157:1195–1203.CrossRefGoogle ScholarPubMed
10.Clark, LA, Watson, D. Tripartite model of anxiety and depression: psychometric evidence and taxonomic implications. J Abnorm Psychol. 1991;100:316–336.CrossRefGoogle ScholarPubMed
11.Parker, G, Roy, K, Mitchell, P, Wilhelm, K, Malhi, G, Hadzi-Pavlovic, D. Atypical depression: a reappraisal. Am J Psychiatry. 2002;159:1470–1479.CrossRefGoogle ScholarPubMed
12.Goodwin, FK. Predictors of antidepressant response. Bull Menninger Clin. 1993;57:146–160.Google ScholarPubMed
13.Taylor, BP, Bruder, GE, Stewart, JW, et al.Psychomotor slowing as a predictor of fluoxetine nonresponse in depressed outpatients. Am J Psychiatry. 2006;163:73–78.CrossRefGoogle ScholarPubMed
14.Mitchell, PB. Managing depression in a community setting. Med J Aust. 1997;167:383–388.Google Scholar
15.Mitchell, PB. The new antidepressants—are they worth the cost? Aust Prescriber. 1995;18:82–84.CrossRefGoogle Scholar
16.Janke, W. Clinical efficacy of drugs predicted from drug effects after short-term administration in animals, normal subjects, and patients. Neuropsychobiology. 1985;13:53–54.CrossRefGoogle Scholar
17.Cowdry, R, Goodwin, F. Biological and physiological predictors of drug response. In: van Praag, HM, Lader, Mh, Rafelsen, OJ, eds. Handbook of Biological Psychiatry. 1st ed. New York, NY: Marcel Dekker; 1981:263–308.Google Scholar
18.Bielski, RJ, Friedel, RO. Prediction of tricyclic antidepressant response: a critical review. Arch Gen Psychiatry. 1976;33:1479–1489.CrossRefGoogle ScholarPubMed
19.Joyce, PR, Paykel, ES. Predictors of drug response in depression. Arch Gen Psychiatry. 1989;46:89–99.CrossRefGoogle ScholarPubMed
20.Mayberg, HS, Brannan, SK, Mahurin, RK, et al.Cingulate function in depression: a potential predictor of treatment response. Neuroreport. 1997;8:1057–1061.CrossRefGoogle Scholar
21.Davidson, RJ, Irwin, W, Anderle, MJ, Kalin, NH. The neural substrates of affective processing in depressed patients treated with venlafaxine. Am J Psychiatry. 2003;160:64–75.CrossRefGoogle ScholarPubMed
22.Kemp, AH, Gray, MA, Silberstein, RB, Armstrong, SM, Nathan, PJ. Augmentation of serotonin enhances pleasant and suppresses unpleasant cortical electrophysiological responses to visual emotional stimuli in humans. Neuroimage. 2004;22:1084–1096.CrossRefGoogle ScholarPubMed
23.Kemp, AH, Gray, MA, Line, P, Silberstein, BB, Nathan, PJ. Preliminary electrophysiological evidence for modulation of the processing of negative affect by serotonin. Brain Cogn. 2003;51:198–200.Google Scholar
24.Harmer, CJ, Bhagwagar, Z, Perrett, DI, Vollm, BA, Cowen, PJ, Goodwin, GM. Acute SSRI administration affects the processing of social cues in healthy volunteers. Neuropsychopharmacology. 2003;28:148–152.CrossRefGoogle ScholarPubMed
25.Harmer, CJ, Hill, SA, Taylor, MJ, Cowen, PJ, Goodwin, GM. Toward a neuropsychological theory of antidepressant drug action: increase in positive emotional bias after potentiation of norepinephrine activity. Am J Psychiatry. 2003;160:990–992.CrossRefGoogle Scholar
26.Harmer, CJ, Mackay, CE, Reid, CB, Cowen, PJ, Goodwin, GM. Antidepressant drug treatment modifies the neural processing of nonconscious threat cues. Biol Psychiatry. 2006;59:816–820.CrossRefGoogle ScholarPubMed
27.Segal, ZV, Kennedy, S, Gemar, M, Hood, K, Pedersen, R, Buis, T. Cognitive reactivity to sad mood provocation and the prediction of depressive relapse. Arch Gen Psychiatry. 2006;63:749–755.CrossRefGoogle ScholarPubMed
28.Keller, MB. Past, present, and future directions for defining optimal treatment outcome in depression: remission and beyond. JAMA. 2003;289:3152–3160.CrossRefGoogle ScholarPubMed
29.Souery, D, Papakostas, GI, Trivedi, MH. Treatment-resistant depression. J Clin Psychiatry. 2006;67(suppl 6):16–22.Google ScholarPubMed
30.Keller, MB. Remission versus response: the new gold standard of antidepressant care. J Clin Psychiatry. 2004;65(suppl 4):53–59.Google ScholarPubMed
31.Kleindienst, N, Engel, R, Greil, W. Which clinical factors predict response to prophylactic lithium? A systematic review for bipolar disorders. Bipolar Disord. 2005;7:404–417.CrossRefGoogle ScholarPubMed
32.Benazzi, F. The continuum/spectrum concept of mood disorders: is mixed depression the basic link? Eur Arch Psychiatry Clin Neurosci. 2006;256:512–515.CrossRefGoogle ScholarPubMed
33.Alexopoulos, GS, Meyers, BS, Young, RC, Kakuma, T, Silbersweig, D, Charlson, M. Clinically defined vascular depression. Am J Psychiatry. 1997;154:562–565.Google ScholarPubMed
34.Herrmann, LL, Le Masurier, M, Ebmeier, KP. White matter hyperintensities in late life depression: a systematic review. J Neural Neurosurg Psychiatry. 2007;79:619–624.CrossRefGoogle ScholarPubMed
35.Hirschfeld, RMA. Psychosocial predictors of outcome in depression. In: Bloom, FE, Kupfer, DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 2002:1113–1121.Google Scholar
36.Bagby, RM, Ryder, AG, Cristi, C. Psychosocial and clinical predictors of response to pharmacotherapy for depression. J Psychiatry Neurosci. 2002;27:250–257.Google Scholar
37.Sotsky, SM, Glass, DR, Shea, MT, et al.Patient predictors of response to psychotherapy and pharmacotherapy: findings in the NIMH Treatment of Depression Collaborative Research Program. Am J Psychiatry. 1991;148:997–1008.Google ScholarPubMed
38.National Institute for Clinical Excellence. Depression: Management of Depression in Primary and Secondary Care. London, UK: National Institute for Clinical Excellence (NICE); 2004.Google Scholar
39.Montgomery, SA, Baldwin, DS, Blier, P, et al.Which antidepressants have demonstrated superior efficacy? A review of the evidence. Int Clin Psychopharmacol. 2007;22:323–329.CrossRefGoogle Scholar
40.Einarson, TR. Evidence based review of escitalopram in treating major depressive disorder in primary care. Int Clin Psychopharmacol. 2004;19:305–310.CrossRefGoogle ScholarPubMed
41.Fernandez, JL, Montgomery, S, Francois, C. Evaluation of the cost effectiveness of escitalopram versus venlafaxine XR in major depressive disorder. Pharmacoeconomics. 2005;23:155–167.CrossRefGoogle ScholarPubMed
42.Eckert, L, Falissard, B. Using meta-regression in performing indirect-comparisons: comparing escitalopram with venlafaxine XR. Curr Med Res Opin. 2006;22:2313–2321.CrossRefGoogle ScholarPubMed
43.Liebowitz, MR, Quitkin, FM, Stewart, JW, et al.Antidepressant specificity in atypical depression. Arch Gen Psychiatry. 1988;45:129–137.CrossRefGoogle ScholarPubMed
44.Thase, ME, Trivedi, MH, Rush, AJ. MAOIs in the contemporary treatment of depression. Neuropsychopharmacology. 1995;12:185–219.CrossRefGoogle ScholarPubMed
45.Anderson, IM. SSRIS versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability. Depress Anxiety. 1998;7:11–17.3.0.CO;2-I>CrossRefGoogle ScholarPubMed
46.Souery, D, Oswald, P, Massat, I, et al.Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. J Clin Psychiatry. 2007;68:1062–1070.CrossRefGoogle ScholarPubMed
47.Fava, M, Rush, AJ, Alpert, JE, et al.Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry. 2008;165:342–351.CrossRefGoogle ScholarPubMed
48.Davidson, JR, Meoni, P, Haudiquet, V, Cantillon, M, Hackett, D. Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms. Depress Anxiety. 2002;16:4–13.CrossRefGoogle ScholarPubMed
49.Bakish, D. The patient with comorbid depression and anxiety: the unmet need. J Clin Psychiatry. 1999;60(suppl 6):20–24.Google ScholarPubMed
50.Janssen, J, Pol, HE, Schnack, HG, et al.Cerebral volume measurements and subcortical white matter lesions and short-term treatment response in late life depression. Int J Geriatr Psychiatry. 2007;22:468–474.CrossRefGoogle ScholarPubMed
51.Alexopoulos, GS, Meyers, BS, Young, RC, Campbell, S, Silbersweig, D, Charlson, M. ‘Vascular depression’ hypothesis. Arch Gen Psychiatry. 1997;54:915–922.CrossRefGoogle ScholarPubMed
52.Taylor, WD, Steffens, DC, MacFall, JR, et al.White matter hyperintensity progression and late-life depression outcomes. Arch Gen Psychiatry. 2003;60:1090–1096.CrossRefGoogle ScholarPubMed
53.Baldwin, R, Jeffries, S, Jackson, A, et al.Treatment response in late-onset depression: relationship to neuropsychological, neuroradiological and vascular risk factors. Psychol Med. 2004;34:125–136.CrossRefGoogle ScholarPubMed
54.Salloway, S, Malloy, P, Kohn, R, et al.MRI and neuropsychological differences in early- and late-life-onset geriatric depression. Neurology. 1996;46:1567–1574.CrossRefGoogle ScholarPubMed
55.Teodorczuk, A, O'Brien, JT, Firbank, MJ, et al.White matter changes and late-life depressive symptoms: longitudinal study. Br J Psychiatry. 2007;191:212–217.CrossRefGoogle ScholarPubMed
56.Simpson, SW, Jackson, A, Baldwin, RC, Burns, A. 1997 IPA/Bayer Research Awards in Psychogeriatrics. Subcortical hyperintensities in late-life depression: acute response to treatment and neuropsychological impairment. Int Psychogeriatr. 1997;9(3):257–275.CrossRefGoogle ScholarPubMed
57.Joffe, RT, Gatt, JM, Kemp, AH, et al.Brain derived neurotrophic factor Val66Met polymorphism, the five factor model of personality and hippocampal volume: Implications for depressive illness. Hum Brain Mapp. Jun 11 2008. [Epub ahead of print].Google Scholar
58.Shifman, S, Bhomra, A, Smiley, S, et al.A whole genome association study of neuroticism using DNA pooling. Mol Psychiatry. 2008;13:302–312.CrossRefGoogle ScholarPubMed
59.van den Oord, EJ, Kuo, PH, Hartmann, AM, et al.Genomewide association analysis followed by a replication study implicates a novel candidate gene for neuroticism. Arch Gen Psychiatry. 2008;65(9):1062–1071.CrossRefGoogle ScholarPubMed
60.Hettema, JM, Neale, MC, Myers, JM, Prescott, CA, Kendler, KS. A population-based twin study of the relationship between neuroticism and internalizing disorders. Am J Psychiatry. 2006;163:857–864.CrossRefGoogle ScholarPubMed
61.Quitkin, FM. Placebos, drug effects, and study design: a clinician's guide. Am J Psychiatry. 1999;156:829–836.CrossRefGoogle ScholarPubMed
62.Peselow, ED, Fieve, RR, DiFiglia, C, Nelson, EC, Cloninger, CR. Personality traits and response to desipramine. The tridimensional personality questionnaire as a predictor of response to nefazodone treatment of depression. J Affect Disord. 1992;24:209–216.CrossRefGoogle Scholar
63.Nelson, EC, Cloninger, CR. The tridimensional personality questionnaire as a predictor of response to nefazodone treatment of depression. J Affect Disord. 1995;35:51–57.CrossRefGoogle ScholarPubMed
64.Clark, LA, Watson, D, Mineka, S. Temperament, personality, and the mood and anxiety disorders. J Abnorm Psychol. 1994;103:103–116.CrossRefGoogle ScholarPubMed
65.Mulder, RT, Joyce, PR, Luty, SE. The relationship of personality disorders to treatment outcome in depressed outpatients. J Clin Psychiatry. 2003;64:259–264.CrossRefGoogle ScholarPubMed
66.Kaufman, J, Charney, D. Effects of early stress on brain structure and function: implications for understanding the relationship between child maltreatment and depression. Dev Psychopathol. 2001;13:451–471.CrossRefGoogle ScholarPubMed
67.Nemeroff, CB, Heim, CM, Thase, ME, et al.Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma. Proc Natl Acad Sci U S A. 2003;100:14293–14296.CrossRefGoogle ScholarPubMed
68.Papakostas, GI, Petersen, T, Denninger, JW, et al.Psychosocial functioning during the treatment of major depressive disorder with fluoxetine. J Clin Psychopharmacol. 2004;24:507–511.CrossRefGoogle ScholarPubMed
69.Tedlow, J, Fava, M. Uebelacker, L, Nierenberg, AA, Alpert, JE, Rosenbaum, J. Outcome definitions and predictors in depression. Psychother Psychosom. 1998;67:266–270.CrossRefGoogle ScholarPubMed
70.Trivedi, MH, Baker, SM. Clinical significance of monitoring early symptom change to predict outcome. J Clin Psychiatry. 2001;62:27–33.Google ScholarPubMed
71.Mulder, RT, Joyce, PR, Sullivan, PF, Oakley-Browne, MA. Intimate bonds in depression. J Affect Disord. 1996;40:175–178.CrossRefGoogle ScholarPubMed
72.Lam, RW, Bartley, S, Yatham, LN, Tarn, EM, Zis, AP. Clinical predictors of short-term outcome in electroconvulsive therapy. Can J Psychiatry. 1999;44:158–163.CrossRefGoogle ScholarPubMed
73.Moller, HJ, Fischer, G, von Zerssen, D. Prediction of therapeutic response in acute treatment with antidepressants. Results of an empirical study involving 159 endogenous depressive inpatients. Eur Arch Psychiatry Neurol Sci. 1987;236:349–357.CrossRefGoogle ScholarPubMed
74.Moller, HJ, Krokenberger, M, von Zerssen, D. Prediction of short-term outcome of neurotic-depressive inpatients. Results of an empirical study of 134 inpatients. Bur Arch Psychiatry Clin Neurosci. 1993;242:301–309.CrossRefGoogle ScholarPubMed
75.Small, GW, Hamilton, SH, Bystritsky, A, Meyers, BS, Nemeroff, CB. Clinical response predictors in a double-blind, placebo-controlled trial of fluoxetine for geriatric major depression. Fluoxetine Collaborative Study Group. Int Psychogeriatr. 1995;7:41–53.CrossRefGoogle Scholar
76.Gartlehner, G, Hansen, RA, Thieda, P, et al.Comparative Effectiveness of Second-Generation Antidepressants in the Pharmacologic Treatment of Adult Depression. Comparative Effectiveness Review No. 7. (Prepared by RTI International-University of North Carolina Evidence-based Practice Center under Contract No. 290-02-0016.). Rockville, MD: Agency for Healthcare Research and Quality; 2007. Comparative Effectiveness Review No. 7.Google ScholarPubMed
77.Mayberg, HS, Silva, JA, Brannan, SK, et al.The functional neuroanatomy of the placebo effect. Am J Psychiatry. 2002;159:728–737.CrossRefGoogle ScholarPubMed
78.Goodwin, GM. Neuropsychological and neuroimaging evidence for the involvement of the frontal lobes in depression. J Psychopharmacol. 1997;11:115–122.CrossRefGoogle ScholarPubMed
79.Rogers, MA, Kasai, K, Koji, M, et al.Executive and prefrontal dysfunction in unipolar depression: a review of neuropsychological and imaging evidence. Neurosci Res. 2004;50:1–11.CrossRefGoogle ScholarPubMed
80.Austin, MP, Mitchell, P, Goodwin, GM. Cognitive deficits in depression: possible implications for functional neuropathology. Br J Psychiatry. 2001;178:200–206.CrossRefGoogle ScholarPubMed
81.Rowe, DL, Cooper, NJ, Liddell, BJ, Clark, CR, Gordon, E, Williams, LM. Brain structure and function correlates of general and social cognition. J Integr Neurosci. 2007;6:35–74.CrossRefGoogle ScholarPubMed
82.Williams, LM, Whitford, TJ, Flynn, G, et al.General and social cognition in first episode schizophrenia: identification of separable factors and prediction of functional outcome using the IntegNeuro test battery. Schizophr Res. 2008;99:182–191.CrossRefGoogle ScholarPubMed
83.Dunkin, JJ, Leuchter, AF, Cook, IA, Kasl-Godley, JE, Abrams, M, Rosenberg-Thompson, S. Executive dysfunction predicts nonresponse to fluoxetine in major depression. J Affect Disord. 2000;60:13–23.CrossRefGoogle ScholarPubMed
84.Gorlyn, M, Keilp, JG, Grunebaum, MF, et al.Neuropsychological characteristics as predictors of SSRI treatment response in depressed subjects. J Neural Transm. 2008;115:1213–1219.CrossRefGoogle ScholarPubMed
85.Herrmann, LL, Goodwin, GM, Ebmeier, KP. The cognitive neuropsychology of depression in the elderly. Psychol Med. 2007;37:1693–1702.CrossRefGoogle ScholarPubMed
86.Bruder, GE, Stewart, JW, Merrier, MA, et al.Outcome of cognitive-behavioral therapy for depression: relation to hemispheric dominance for verbal processing. J Abnorm Psychol. 1997;106:138–144.CrossRefGoogle ScholarPubMed
87.Bruder, GE, Otto, MW, McGrath, PJ, et al.Dichotic listening before and after fluoxetine treatment for major depression: relations of laterally to therapeutic response. Neuropsychopharmacology. 1996;15:171–179.CrossRefGoogle Scholar
88.Bruder, GE, Stewart, JW, Voglmaier, MM, et al.Cerebral laterality and depression: relations of perceptual asymmetry to outcome of treatment with tricyclic antidepressants. Neuropsychopharmacology. 1990;3:1–10.Google ScholarPubMed
89.Bruder, GE, Stewart, JW, Schaller, JD, McGrath, PJ. Predicting therapeutic response to secondary treatment with bupropion: dichotic listening tests of functional brain asymmetry. Psychiatry Res. 2007;153:137–143.CrossRefGoogle ScholarPubMed
90.Flament, MF, Lane, RM, Zhu, R, Ying, Z. Predictors of an acute antidepressant response to fluoxetine and sertraline. Int Clin Psychopharmacol. 1999;14:259–275.CrossRefGoogle ScholarPubMed
91.Caligiuri, MP, Gentili, V, Eberson, S, Kelsoe, J, Rapaport, M, Gillin, JC. A quantitative neuromotor predictor of antidepressant non-response in patients with major depression. J Affect Disord. 2003;77:135–141.CrossRefGoogle ScholarPubMed
92.Malhi, GS, Parker, GB, Greenwood, J. Structural and functional models of depression: from subtypes to substrates. Acta Psychiatr Scand. 2005;111:94–105.CrossRefGoogle ScholarPubMed
93.Rush, AJ, Wisniewski, SR, Warden, D, et al.Selecting among second-step antidepressant medication monotherapies: are clinical, demographic, or first-step treatment results informative? Arch Gen Psychiatry. 2008;65:870–880.CrossRefGoogle ScholarPubMed
94.Fava, M, Rush, AJ, Trivedi, MH, et al.Background and rationale for the sequenced treatment alternatives to relieve depression |STAR*D) study. Psychiatr Clin North Am. 2003;26:457–494.CrossRefGoogle ScholarPubMed
95.Rush, AJ, Fava, M, Wisniewski, SR, et al.Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials. 2004;25:119–142.CrossRefGoogle ScholarPubMed
96.Kampf-Sherf, O, Zlotogorski, Z, Gilboa, A, et al.Neuropsychological functioning in major depression and responsiveness to selective serotonin reuptake inhibitors antidepressants. J Affect Disord. 2004;82:453–459.Google ScholarPubMed
97.Kramer-Ginsberg, E, Greenwald, BS, Krishnan, KR, et al.Neuropsychological functioning and MRI signal hyperintensities in geriatric depression. Am J Psychiatry. 1999;156:438–444.Google ScholarPubMed
98.Stahl, SM, Zhang, L, Damatarca, C, Grady, M. Brain circuits determine destiny in depression: a novel approach to the psychopharmacology of wakefulness, fatigue, and executive dysfunction in major depressive disorder. J Clin Psychiatry. 2003;64:6–17.Google ScholarPubMed
99.de Groot, MH, Nolen, WA, Huijsman, AM, Bouvy, PF. Lateralized neuropsychological functioning in depressive patients before and after drug therapy. Biol Psychiatry. 1996;40:1282–1287.CrossRefGoogle ScholarPubMed
100.Heller, W. Neuropsychological mechanisms of individual differences in emotion, personality, and arousal. Neuropsychology. 1993;7:476–489.CrossRefGoogle Scholar
101.Otto, MW, Fava, M, Rosenbaum, JF, Murphy, CF. Perceptual asymmetry, plasma cortisol, and response to treatment in depressed outpatients. Biol Psychiatry. 1991;30:703–710.CrossRefGoogle ScholarPubMed
102.Venn, HR, Watson, S, Gallagher, P, Young, AH. Facial expression perception: an objective outcome measure for treatment studies in mood disorders? Int J Neuropsychopharmacol. 2006;9:229–245.CrossRefGoogle ScholarPubMed
103.Keefe, RS. The contribution of neuropsychology to psychiatry. Am J Psychiatry. 1995;152:6–15.Google ScholarPubMed
104.Saletu, B, Grunberger, J, Linzmayer, L. On central effects of serotonin re-uptake inhibitors: quantitative EEG and psychometric studies with sertraline and zimelidine. J Neural Transm. 1986;67:241–266.CrossRefGoogle ScholarPubMed
105.Luthringer, R, Dago, KT, Patat, A, et al.Pharmacoelectroencephalographic profile of befloxatone, a new reversible MAO-A inhibitor, in healthy subjects. Neuropsychobiology. 1996;34:98–105.CrossRefGoogle ScholarPubMed
106.Argyropoulos, SV, Wilson, SJ. Sleep disturbances in depression and the effects of antidepressants. Int Rev Psychiatry. 2005;17:237–245.CrossRefGoogle ScholarPubMed
107.Benca, RM, Obermeyer, WH, Thisted, RA, Gillin, JC. Sleep and psychiatric disorders. A meta-analysis. Arch Gen Psychiatry. 1992;49:651–668; discussion 669-670.CrossRefGoogle ScholarPubMed
108.Taylor, MA, Fink, M. Restoring melancholia in the classification of mood disorders. J Affect Disord. 2008;105:1–14.CrossRefGoogle ScholarPubMed
109.Thase, ME. Depression, sleep, and antidepressants. J Clin Psychiatry. 1998;59(suppl 4):55–65.Google ScholarPubMed
110.Vogel, GW, Buffenstein, A, Minter, K, Hennessey, A. Drug effects on REM sleep and on endogenous depression. Neurosci Biobehav Rev. 1990;14:49–63.CrossRefGoogle ScholarPubMed
111.Gillin, JC, Wyatt, RJ, Fram, D, Snyder, F. The relationship between changes in REM sleep and clinical improvement in depressed patients treated with amitriptyline. Psychopharmacology (Berl). 1978;59:267–272.CrossRefGoogle Scholar
112.Kupfer, DJ, Spiker, DG, Coble, PA, Neil, JF, Ulrich, R, Shaw, DH. Sleep and treatment prediction in endogenous depression. Am J Psychiatry. 1981;138:429–434.Google ScholarPubMed
113.Ehlers, CL, Havstad, JW, Kupfer, DJ. Estimation of the time course of slow-wave sleep over the night in depressed patients: effects of clomipramine and clinical response. Biol Psychiatry. 1996;39:171–181.CrossRefGoogle ScholarPubMed
114.Luthringer, R, Minot, R, Toussaint, M, Calvi-Gries, F, Schaltenbrand, N, Macher, JP. All-night EEG spectral analysis as a tool for the prediction of clinical response to antidepressant treatment. Biol Psychiatry. 1995;38:98–104.CrossRefGoogle ScholarPubMed
115.Staedt, J, Hunerjager, H, Ruther, E, Stoppe, G. Sleep cluster arousal analysis and treatment response to heterocyclic antidepressants in patients with major depression. J Affect Disord. 1998;49:221–227.CrossRefGoogle ScholarPubMed
116.Buysse, DJ, Hall, M, Begley, A, et al.Sleep and treatment response in depression: new findings using power spectral analysis. Psychiatry Res. 2001;103:51–67.CrossRefGoogle ScholarPubMed
117.Knott, VJ, Telner, JI, Lapierre, YD, Browne, M, Horn, ER. Qantitative EEG in the prediction of antidepressant response to imipramine. J Affect Disord. 1996;39:175–184.CrossRefGoogle Scholar
118.Knott, V, Mahoney, C, Kennedy, S, Evans, K. Pre-treatment EEG and it's relationship to depression severity and paroxetine treatment outcome. Pharmacopsychiatry. 2000;33:201–205.CrossRefGoogle ScholarPubMed
119.Knott, V, Mahoney, C, Kennedy, S, Evans, K. EEG correlates ot acute and chronic paroxetine treatment in depression. J Affect Disord. 2002;69:241–249.CrossRefGoogle Scholar
120.Mulert, C, Juckel, G, Brunnmeier, M, et al.Prediction of treatment response in major depression: integration of concepts. J Affect Disord. 2007;98:215–225.CrossRefGoogle Scholar
121.Pizzagalli, D, Pascual-Marqui, RD, Nitschke, JB, et al.Anterior cingulate activity as a predictor of degree of treatment response in major depression: evidence from brain electrical tomography analysis. Am J Psychiatry. 2001;158:405–415.CrossRefGoogle ScholarPubMed
122.Nystrom, C, Matousek, M, Hallstrom, T. Relationships between EEG and biochemical parameters in major depressive disorder. Acta Psychiatr Scand. 1988;77:457–462.CrossRefGoogle ScholarPubMed
123.Nieber, D, Schlegel, S. Relationships between psychomotor retardation and EEG power spectrum in major depression. Neuropsychobiology. 1992;25:20–23.CrossRefGoogle ScholarPubMed
124.Cook, IA, Leuchter, AF, Morgan, M, et al.Early changes in prefrontal activity characterize clinical respondersto antidepressants. Neuropsychopharmacology. 2002;27:120–131.CrossRefGoogle Scholar
125.Prichep, LS, Mas, F, Hollander, E, et al.Quantitative electroencephalographic subtyping of obsessive-compulsive disorder. Psychiatry Res. 1993;50:25–32.CrossRefGoogle ScholarPubMed
126.Suffin, SC, Emory, WH. Neurometric subgroups in attentional and affective disorders and their association with pharmacotherapeutic outcome. Clin Electroencephalogr. 1995;26:76–83.CrossRefGoogle ScholarPubMed
127.Cook, IA, Leuchter, AF, Witte, E, et al.Neurophysiologic predictors of treatment response to fluoxetine in major depression. Psychiatry Res. 1999;85:263–273.CrossRefGoogle ScholarPubMed
128.Leuchter, AF, Cook, IA, Lufkin, RB, et al.Cordance: a new method for assessment of cerebral perfusion and metabolism using quantitative electroencephalography. Neuroimage. 1994;1:208–219.CrossRefGoogle ScholarPubMed
129.Leuchter, AF, Cook, IA, Mena, I, et al.Assessment of cerebral perfusion using quantitative EEG cordance. Psychiatry Res. 1994;55:141–152.CrossRefGoogle ScholarPubMed
130.Leuchter, AF, Uijtdehaage, SH, Cook, IA, O'Hara, R, Mandelkern, M. Relationship between brain electrical activity and cortical perfusion in normal subjects. Psychiatry Res. 1999;90:125–140.CrossRefGoogle ScholarPubMed
131.Cook, IA, Leuchter, AF, Witte, E, et al.Neurophysiologic predictors of treatment response to fluoxetine in major depression. Psychiatry Res. 1999;85:263–273.CrossRefGoogle ScholarPubMed
132.Cook, IA, Leuchter, AF. Prefrontal changes and treatment response prediction in depression. Semin Clin Neuropsychiatry. 2001;6:113–120.CrossRefGoogle ScholarPubMed
133.Leuchter, AF, Cook, IA, Uijtdehaage, SH, et al.Brain structure and function and the outcomes of treatment for depression [published erratum appears in J Clin Psychiatry. 1998:5932]. J Clin Psychiatry. 1997;58(suppl 16):22–31.Google Scholar
134.Cook, IA, Leuchter, AF, Morgan, ML, Stubbeman, W, Siegman, B, Abrams, M. Changes in prefrontal activity characterize clinical response in SSRI nonresponders: a pilot study. J Psychiatr Res. 2005;39:461–466.CrossRefGoogle ScholarPubMed
135.Leuchter, AF, Cook, IA, Witte, EA, Morgan, M, Abrams, M. Changes in brain function of depressed subjects during treatment with placebo. Am J Psychiatry. 2002;159:122–129.CrossRefGoogle Scholar
136.Kemp, AH, Silberstein, RB, Armstrong, SM, Nathan, PJ. Gender differences in the cortical electro-physiological processing of visual emotional stimuli. Neuroimage. 2004;21:632–646.CrossRefGoogle Scholar
137.Diego, MA, Field, T, Hernandez-Reif, M. CES-D depression scores are correlated with frontal EEG alpha asymmetry. Depress Anxiety. 2001;13:32–37.3.0.CO;2-G>CrossRefGoogle ScholarPubMed
138.Davidson, RJ, Tomarken, AJ. Laterality and emotion: An electrophysiological approach. In: Boller, F, Grafman, J, eds. Handbook of Neuropsychology. vol 3. Amsterdam, the Netherlands: Elsevier; 1989:419–441.Google Scholar
139.Mathersul, D, Williams, LM, Hopkinson, PJ, Kemp, AH. Investigating models of affect: relationships among EEG alpha asymmetry, depression, and anxiety. Emotion. 2008;8:560–572.CrossRefGoogle ScholarPubMed
140.Reid, SA, Duke, LM, Allen, JJ. Resting frontal electroencephalographic asymmetry in depression: inconsistencies suggest the need to identify mediating factors. Psychophysiology. 1998;35:389–404.CrossRefGoogle ScholarPubMed
141.Minnix, JA, Kline, JP, Blackhart, GC, Pettit, JW, Perez, M, Joiner, TE. Relative left-frontal activity is associated with increased depression in high reassurance-seekers. Biol Psychol. 2004;67:145–155.CrossRefGoogle ScholarPubMed
142.Bruder, GE, Stewart, JW, Tenke, CE, et al.Electroencephalographic and perceptual asymmetry differences between responders and nonresponders to an SSRI antidepressant. Biol Psychiatry. 2001;49:416–425.CrossRefGoogle Scholar
143.Hegerl, U, Juckel, G. Intensity dependence of auditory evoked potentials as an indicator of central serotonergic neurotransmission: a new hypothesis. Biol Psychiatry. 1993;33:173–187.CrossRefGoogle ScholarPubMed
144.Mulert, C, Juckel, G, Augustin, H, Hegerl, U. Comparison between the analysis of the loudness dependency of the auditory N1/P2 component with LORETA and dipole source analysis in the prediction of treatment response to the selective serotonin reuptake inhibitor citalopram in major depression. Clin Neurophysiol. 2002;113:1566–1572.CrossRefGoogle Scholar
145.Paige, SR, Fitzpatrick, DF, Kline, JP, Balogh, SE, Hendricks, SE. Event-related potential amplitude/intensity slopes predict response to antidepressants. Neuropsychobiology. 1994;30:197–201.CrossRefGoogle Scholar
146.Linka, T, Muller, BW, Bender, S, Sartory, G, Gastpar, M. The intensity dependence of auditory evoked ERP components predicts responsiveness to reboxetine treatment in major depression. Pharmacopsychiatry. 2005;38:139–143.CrossRefGoogle ScholarPubMed
147.Nathan, PJ, Segrave, R, Phan, KL, O'Neill, B, Croft, RJ. Direct evidence that acutely enhancing serotonin with the selective serotonin reuptake inhibitor citalopram modulates the loudness dependence of the auditory evoked potential (LDAEP) marker of central serotonin function. Hum Psychopharmacol. 2006;21:47–52.CrossRefGoogle ScholarPubMed
148.Paige, SR, Hendricks, SE, Fitzpatrick, DF, Balogh, S, Burke, WJ. Amplitude/intensity functions of auditory event-related potentials predict responsiveness to bupropion in major depressive disorder. Psychopharmacol Bull. 1995;31:243–248.Google ScholarPubMed
149.Nathan, PJ, O'Neill, B, Croft, RJ. Is the loudness dependence of the auditory evoked potential a sensitive and selective in vivo marker of central serotonergic function? Neuropsychopharmacology. 2005;30:1584–1585; author reply 1586-1587.CrossRefGoogle ScholarPubMed
150.Bruder, GE, Tenke, CE, Stewart, JW, et al.Brain event-related potentials to complex tones in depressed patients: relations to perceptual asymmetry and clinical features. Psychophysiology. 1995;32:373–381.CrossRefGoogle ScholarPubMed
151.Bruder, GE, Tenke, CE, Stewart, JW, McGrath, PJ, Quitkin, FM. Predictors of therapeutic response to treatments for depression: a review of electrophysiologic and dichotic listening studies. CNS Spectr. 1999;4:30–36.CrossRefGoogle ScholarPubMed
152.Kalayam, B, Alexopoulos, GS. Prefrontal dysfunction and treatment response in geriatric depression. Arch Gen Psychiatry. 1999;56:713–718.CrossRefGoogle ScholarPubMed
153.Drevets, WC. Prefrontal cortical-amygdalar metabolism in major depression. Ann N Y Acad Sci. 1999;877:614–637.CrossRefGoogle ScholarPubMed
154.Wu, JC, Buchsbaum, M, Bunney, WE Jr. Clinicai neurochemical implications of sleep deprivation's effects on the anterior cingulate of depressed responders. Neuropsychopharmacology. 2001;25(suppl):s74–s78.CrossRefGoogle Scholar
155.Dougherty, DD, Rauch, SL. Brain correlates of antidepressant treatment outcome from neuroimaging studies in depression. Psychiatr Clin North Am. 2007;30:91–103.CrossRefGoogle ScholarPubMed
156.Mayberg, HS. Modulating dysfunctional limbic-cortical circuits in depression: towards development of brain-based algorithms for diagnosis and optimised treatment. Br Med Bull. 2003;65:193–207.CrossRefGoogle ScholarPubMed
157.Drevets, WC. Neuroimaging studies of mood disorders. Biol Psychiatry. 2000;48:813–829.CrossRefGoogle ScholarPubMed
158.Mayberg, HS, Liotti, M, Brannan, SK, et al.Reciprocal limbic-cortical function and negative mood: converging PET findings in depression and normal sadness. Am J Psychiatry. 1999;156:675–682.Google ScholarPubMed
159.Wu, J, Buchsbaum, MS, Gillin, JC, et al.Prediction of antidepressant effects of sleep deprivation by metabolic rates in the ventral anterior cingulate and medial prefrontal cortex. Am J Psychiatry. 1999;156:1149–1158.Google ScholarPubMed
160.Brody, AL, Saxena, S, Silverman, DH, et al.Brain metabolic changes in major depressive disorder from pre-to post-treatment with paroxetine. Psychiatry Res. 1999;91:127–139.CrossRefGoogle ScholarPubMed
161.Ebert, D, Feistel, H, Barocka, A, Kaschkfl, W. Increased limbic blood flow and total sleep depriva-tion in major depression with melancholia. Psychiatry Res. 1994;55:101–109.CrossRefGoogle ScholarPubMed
162.Wu, JC, Gillin, JC, Buchsbaum, MS, Hershey, T, Johnson, JC, Bunney, WE Jr. Effect of sleep deprivation on brain metabolism of depressed patients. Am J Psychiatry. 1992;149:538–543.Google ScholarPubMed
163.Chen, CH, Ridler, K, Suckling, J, et al.Brain imaging correlates of depressive symptom severity and predictors of symptom improvement after antidepressant treatment. Biol Psychiatry. 2007;62:407–41.CrossRefGoogle ScholarPubMed
164.Fu, CH, Williams, SC, Cleare, AJ, et al.Attenuation of the neural response to sad faces in major depression by antidepressant treatment: a prospective, event-related functional magnetic reso-nance imaging study. Arch Gen Psychiatry. 2004;61:877–889.CrossRefGoogle Scholar
165.Siegle, GJ, Carter, CS, Thase, ME. Use of FMRI to predict recovery from unipolar depression with cognitive behavior therapy. Am J Psychiatry. 2006;163:735–738.CrossRefGoogle ScholarPubMed
166.Devinsky, O, Morrell, MJ, Vogt, BA. Contributions of anterior cingulate cortex to behaviour. Brain. 1995;118(pt 1):279–306.CrossRefGoogle ScholarPubMed
167.Bush, G, Luu, P, Posner, MI. Cognitive and emotional influences in anterior cingulate cortex. Trends Cogn Sci. 2000;4:215–222.CrossRefGoogle ScholarPubMed
168.Mayberg, HS, Lozano, AM, Voon, V, et al.Deep brain stimulation for treatment-resistant depression. Neuron. 2005;45:651–660.CrossRefGoogle ScholarPubMed
169.Johansen-Berg, H, Gutman, DA, Behrens, TE, et al.Anatomical connectivity of the subgenual cingulate region targeted with deep brain stimulation for treatment-resistant depression. Cereb Cortex. 2008;18:1374–1383.CrossRefGoogle ScholarPubMed
170.Fu, CH, Williams, SC, Brammer, MJ, et al.Neural responses to happy facial expressions in major depression following antidepressant treatment. Am J Psychiatry. 2007;164:599–607.CrossRefGoogle ScholarPubMed
171.Drevets, WC, Price, JL, Furey, ML. Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression. Brain Struct Funct. 2008;213:93–118.CrossRefGoogle ScholarPubMed
172.Sheline, YI, Barch, DM, Donnelly, JM, Ollinger, JM, Snyder, AZ, Mintun, MA. Increased amygdala response to masked emotional faces in depressed subjects resolves with antidepressant treatment: an fMRI study. Biol Psychiatry. 2001;50:651–658.CrossRefGoogle ScholarPubMed
173.Robertson, B, Wang, L, Diaz, MT, et al.Effect of bupropion extended release on negative emotion processing in major depressive disorder: a pilot functional magnetic resonance imaging study. J Clin Psychiatry. 2007;68:261–267.CrossRefGoogle ScholarPubMed
174.Canli, T, Cooney, RE, Goldin, P, et al.Amygdala reactivity to emotional faces predicts improvement in major depression. Neuroreport. 2005;16:1267–1270.CrossRefGoogle ScholarPubMed
175.Abercrombie, HC, Schaefer, SM, Larson, CL, et al.Metabolic rate in the right amygdala predicts negative affect in depressed patients. Neuroreport. 1998;9:3301–3307.CrossRefGoogle ScholarPubMed
176.Drevets, WC, Videen, TO, Price, JL, Preskorn, SH, Carmichael, ST, Raichle, ME. A functional anatomical study of unipolar depression. J Neurosci. 1992;12:3628–3641.CrossRefGoogle ScholarPubMed
177.Brody, AL, Saxena, S, Stoessel, P, et al.Regional brain metabolic changes in patients with major depression treated with either paroxetine or interpersonal therapy: preliminary findings. Arch Gen Psychiatry. 2001;58:631–640.CrossRefGoogle ScholarPubMed
178.Martin, SD, Martin, E, Rai, SS, Richardson, MA, Royall, R. Brain blood flow changes in depressed patients treated with interpersonal psychotherapy or venlafaxine hydrochloride: preliminary findings. Arch Gen Psychiatry. 2001;58:641–648.CrossRefGoogle ScholarPubMed
179.Goldapple, K, Segal, Z, Garson, C, et al.Modulation of cortical-limbic pathways in major depression: treatment-specific effects of cognitive behavior therapy. Arch Gen Psychiatry. 2004;61:34–41.CrossRefGoogle ScholarPubMed
180.Kennedy, SH, Konarski, JZ, Segal, ZV, et al.Differences in brain glucose metabolism between responders to CBT and venlafaxine in a 16-week randomized controlled trial. Am J Psychiatry. 2007;164:778–788.CrossRefGoogle Scholar
181.Little, JT, Ketter, TA, Kimbrell, TA, et al.Bupropion and venlafaxine responders differ in pretreatment regional cerebral metabolism in unipolar depression. Biol Psychiatry. 2005;57:220–228.CrossRefGoogle ScholarPubMed
182.Pillay, SS, Yurgelun-Todd, DA, Bonello, CM, Lafer, B, Fava, M, Renshaw, PF. A quantitative magnetic resonance imaging study of cerebral and cerebellar gray matter volume in primary unipolar major depression: relationship to treatment response and clinical severity. Biol Psychiatry. 1997;42:79–84.CrossRefGoogle ScholarPubMed
183.Rogers, MA, Bradshaw, JL, Pantelis, C, Phillips, JG. Frontostriatal deficits in unipolar major depression. Brain Res Bull. 1998;47:297–310.CrossRefGoogle ScholarPubMed
184.Sheline, YI, Gado, MH, Kraemer, HC. Untreated depression and hippocampal volume loss. Am J Psychiatry. 2003;160:1516–1518.CrossRefGoogle ScholarPubMed
185.Campbell, S, Marriott, M, Nahmias, C, MacQueen, GM. Lower hippocampai volume in patients suffering from depression: a meta-analysis. Am J Psychiatry. 2004;161:598–607.CrossRefGoogle Scholar
186.Videbech, P, Ravnkilde, B. Hippocampal volume and depression: a meta-analysis of MRI studies. Am J Psychiatry. 2004;161:1957–1966.CrossRefGoogle ScholarPubMed
187.Dranovsky, A, Hen, R. Hippocampal neurogenesis: regulation by stress and antidepressants. Biol Psychiatry. 2006;59:1136–1143.CrossRefGoogle ScholarPubMed
188.Shah, PJ, Ebmeier, KP, Glabus, MF, Goodwin, GM. Cortical grey matter reductions associated with treatment-resistant chronic unipolar depression. Controlled magnetic resonance imaging study. Br J Psychiatry. 1998;172:527–532.CrossRefGoogle ScholarPubMed
189.Hsieh, MH, McQuoid, DR, Levy, RM, Payne, ME, MacFall, JR, Steffens, DC. Hippocampal volume and antidepressant response in geriatric depression. Int J Geriatr Psychiatry. 2002;17:519–525.CrossRefGoogle ScholarPubMed
190.Malhotra, AK, Murphy, GM Jr., Kennedy, JL. Pharmacogenetics of psychotropic drug response. Am J Psychiatry. 2004;161(5):780–796.CrossRefGoogle ScholarPubMed
191.Serretti, A, Artioli, P. From molecular biology to pharmacogenetics: a review of the literature on antidepressant treatment and suggestions of possible candidate genes. Psychopharmacology (Berl). 2004;174:490–503.CrossRefGoogle ScholarPubMed
192.Steimer, W, Muller, B, Leucht, S, Kissling, W. Pharmacogenetics: a new diagnostic tool in the management of antidepressive drug therapy. Clin Chim Acta. 2001;308:33–41.CrossRefGoogle ScholarPubMed
193.Binder, EB, Holsboer, F. Pharmacogenomics and antidepressant drugs. Ann Med. 2006;38:82–94.CrossRefGoogle ScholarPubMed
194.Lee, MS. Role of genetic polymorphisms related to neurotransmitters and cytochrome P-450 enzymes in response to antidepressants. Drugs Today (Barc). 2007;43:569–581.CrossRefGoogle Scholar
195.Charney, DS. Monoamine dysfunction and the pathophysiology and treatment of depression. J Clin Psychiatry. 1998;59:11–14.Google ScholarPubMed
196.Schildkraut, JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am JPsychiatry. 1965;122:509–522.CrossRefGoogle ScholarPubMed
197.Hindmarch, I. Expanding the horizons of depression: beyond the monoamine hypothesis. Hum Psychopharmacol. 2001;16:203–218.CrossRefGoogle ScholarPubMed
198.Wong, ML, O'Kirwan, F, Hannestad, JP, Irizarry, KJ, Elashoff, D, Licinio, J. St John's wort and imipramine-induced gene expression profiles identify cellular functions relevant to antidepressant action and novel pharmacogenetic candidates for the phenotype of antidepressant treatment response. Mol Psychiatry. 2004;9:237–251.CrossRefGoogle ScholarPubMed
199.Duman, RS, Monteggia, LM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry. 2006;59:1116–1127.CrossRefGoogle ScholarPubMed
200.Malberg, JE, Blendy, JA. Antidepressant action: to the nucleus and beyond. Trends Pharmacol Sci. 2005;26:631–638.CrossRefGoogle ScholarPubMed
201.Sapolsky, RM. Is impaired neurogenesis relevant to the affective symptoms of depression? Biol Psychiatry. 2004;56:137–139.CrossRefGoogle ScholarPubMed
202.Gold, PW, Chrousos, GP. Organization of the stress system and its dysregulation in melancholic and atypical depression: high vs low CRH/NE states. Mol Psychiatry. 2002;7:254–275.CrossRefGoogle ScholarPubMed
203.Holsboer, F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology. 2000;23:477–501.CrossRefGoogle Scholar
204.Neigh, GN, Nemeroff, CB. Reduced glucocorticoid receptors: consequence or cause of depression? Trends Endocrinol Metab. 2006;17:124–125.CrossRefGoogle ScholarPubMed
205.McMahon, FJ, Buervenich, S, Charney, D, et al.Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet. 2006;78(5):804–814.CrossRefGoogle ScholarPubMed
206.Ohara, K, Nagai, M, Suzuki, Y, Yoshida, K, Tsukamoto, T, Ohara, K. Apolipoprotein E epsilon 4 allele and Japanese late-onset depressive disorders. Biol Psychiatry. 1999;45:308–312.CrossRefGoogle ScholarPubMed
207.Ohara, K, Suzuki, Y, Yoshida, K, Terada, H, Ohara, K. Lack of association between alphai-antichymotrypsin polymorphism and late-onset depressive disorder. Psychiatry Res. 1999;88:221–226.CrossRefGoogle ScholarPubMed
208.Brouwer, JP, Appelhof, BC, Peeters, RP, et al.Thyrotropin, but not a polymorphism in type II deiodinase, predicts response to paroxetine in major depression. Eur J Endocrinol. 2006;154:819–825.CrossRefGoogle Scholar
209.Smits, KM, Smits, LJ, Schouten, JS, Stelma, FF, Nelemans, P, Prins, MH. Influence of SERTPR and STin2 in the serotonin transporter gene on the effect of selective serotonin reuptake inhibitors in depression: a systematic review. Mol Psychiatry. 2004;9:433–441.CrossRefGoogle ScholarPubMed
210.Smeraldi, E, Serretti, A, Artioli, P, Lorenzi, C, Catalano, M. Serotonin transporter gene-linked polymorphic region: possible pharmacogenetic implications of rare variants. Psychiafr Genet. 2006;16:153–158.CrossRefGoogle ScholarPubMed
211.Smeraldi, E, Zanardi, R, Benedetti, F, Di Bella, D, Perez, J, Catalano, M. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry. 1998;3:508–511.CrossRefGoogle ScholarPubMed
212.Pollock, BG, Ferrell, RE, Mulsant, BH, et al.Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology. 2000;23:587–590.CrossRefGoogle ScholarPubMed
213.Zanardi, R, Benedetti, F, Di Bella, D, Catalano, M, Smeraldi, E. Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene. J Clin Psychopharmacol. Feb 2000;20:105–107.CrossRefGoogle ScholarPubMed
214.Kato, M, Fukuda, T, Wakeno, M, et al.Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients. Neuropsychobiology. 2006;53:186–195.CrossRefGoogle ScholarPubMed
215.Kim, DK, Lim, SW, Lee, S, et al.Serotonin transporter gene polymorphism and antidepressant response. Neuroreport. 2000;11:215–219.CrossRefGoogle ScholarPubMed
216.Yoshida, K, Ito, K, Sato, K, et al.Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26:383–386.CrossRefGoogle ScholarPubMed
217.Kim, H, Lim, SW, Kim, S, et al.Monoamine transporter gene polymorphisms and antidepressant response in koreans with late-life depression. JAMA. 2006;296:1609–1618.CrossRefGoogle ScholarPubMed
218.Hu, XZ, Rush, AJ, Chamey, D, et al.Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with rrtajor depression. Arch Gen Psychiatry. 2007;64:783–792.CrossRefGoogle ScholarPubMed
219.Hu, XZ, Lipsky, RH, Zhu, G, et al.Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. Am J Hum Genet. 2006;78:815–826.CrossRefGoogle ScholarPubMed
220.Mandelli, L, Marino, E, Pirovano, A, et al.Interaction between SERTPR and stressful life events on response to antidepressant treatment. Eur Neuropsychopharmacol. September 22 2008. [Epub ahead of print].Google Scholar
221.Yoshida, K, Takahashi, H, Higuchi, H, et al.Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms. Am J Psychiatry. 2004;161:1575–1580.CrossRefGoogle ScholarPubMed
222.Kirchheiner, J, Nickchen, K, Sasse, J, Bauer, M, Roots, I, Brockmoller, J. A 40-basepair VNTR polymorphism in the dopamine transporter (DAT1) gene and the rapid response to antidepressant treatment. Pharmacogenomics J. 2007;7:48–55.CrossRefGoogle ScholarPubMed
223.Yoshida, K, Higuchi, H, Takahashi, H, et al.Influence of the tyrosine hydroxylase val81met polymorphism and catechol-O-methyltransferase val158met polymorphism on the antidepressant effect of milnacipran. Hum Psychopharmacol. 2008;23:121–128.CrossRefGoogle ScholarPubMed
224.Szegedi, A, Rujescu, D, Tadic, A, et al.The catechol-O-methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression. Pharmacogenomics J. 2005;5:49–53.CrossRefGoogle Scholar
225.Tadic, A, Muller, MJ, Rujescu, D, et al.The MAOA T941G polymorphism and short-term treatment response to mirtazapine and paroxetine in major depression. Am J Med Genet B Neuropsychiatr Genet. 2007;144B:325–331.CrossRefGoogle ScholarPubMed
226.Tadic, A, Rujescu, O, Muller, MJ, et al.A monoamine oxidase B gene variant and short-term antidepressant treatment response. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:1370–1377.CrossRefGoogle ScholarPubMed
227.Egan, MF, Kojima, M, Callicott, JH, et al.The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell. 2003;112:257–269.CrossRefGoogle ScholarPubMed
228.Chen, ZY, Jing, D, Bath, KG, et al.Genetic variant BDNF (Val66Met) polymorphism alters anxiety-related behavior. Science. 2006;314:140–143.CrossRefGoogle ScholarPubMed
229.Tsai, SJ, Cheng, CY, Yu, YW, Chen, TJ, Hong, CJ. Association study of a brain-derived neurotrophic-factor genetic polymorphism and major depressive disorders, symptomatology, and antidepressant response. Am J Med Genet B Neuropsychiatr Genet. 2003;123:19–22.CrossRefGoogle Scholar
230.Choi, MJ, Kang, RH, Lim, SW, Oh, KS, Lee, MS. Brain-derived neurotrophic factor gene polymorphism (Val66Met) and citalopram response in major depressive disorder. Brain Res. 2006;1118:176–182.CrossRefGoogle ScholarPubMed
231.Yoshida, K, Higuchi, H, Kamata, M, et al.The G196A polymorphism of the brain-derived neurotrophic factor gene and the antidepressant effect of milnacipran and fluvoxamine. J Psychopharmacol. 2007;21:650–656.CrossRefGoogle ScholarPubMed
232.Comings, DE, MacMurray, JP. Molecular heterosis: a review. Mol Genet Metab. 2000;71:19–31.CrossRefGoogle ScholarPubMed
233.Brouwer, JP, Appelhof, BC, van Rossum, EF, et al.Prediction of treatment response by HPA-axis and gluco-corticoid receptor polymorphisms in major depression. Psychoneuroendocrinology. 2006;31:1154–1163.CrossRefGoogle Scholar
234.Kato, M, Fukuda, T, Serretti, A, et al.ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32:398–404.CrossRefGoogle ScholarPubMed
235.Mihaljevic Peles, A, Bozina, N, Sagud, M, Rojnic Kuzman, M, Lovric, M. MDR1 gene polymorphism: therapeutic response to paroxetine among patients with major depression. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32:1439–1444.CrossRefGoogle ScholarPubMed
236.Scargle, J. Publication Bias: the “File-Drawer Problem” in scientific inference. Journal for Scientific Exploration. 2000;14:91–106.Google Scholar
237.Rosenthal, R. The file drawer problem and tolerance for null results. Psychiatr Bull. 1979;86:638–641.CrossRefGoogle Scholar
238.Gordon, E, Liddell, BJ, Brown, KJ, et al.Integrating objective gene-brain-behavior markers of psychiatric disorders. J Integr Neurosci. 2007;6:1–34.CrossRefGoogle ScholarPubMed
239.Gordon, E, Cooper, N, Rennie, C, Hermens, D, Williams, LM. Integrative neuroscience: the role of a standardized database. Clin EEG Neurosci. 2005;36:64–75.CrossRefGoogle ScholarPubMed
240.Gordon, E, Barnett, KJ, Cooper, NJ, Tran, N, Williams, LM. An integrative neuroscience platform: application to profiles of negativity and positivity bias. Journal of Integrative Neuroscience. 2008;7:1–22.CrossRefGoogle ScholarPubMed
241.Gordon, E. Genomics and Neuromarkers are both required for the era of brain-related “Personalized Medicine.” Personalized Medicine. 2007;4:201–215.CrossRefGoogle Scholar
242.Simons, AD, Gordon, JS, Monroe, SM, Thase, ME. Toward an integration of psychologic, social, and biologic factors in depression: effects on outcome and course of cognitive therapy. J Consult Clin Psychol. 1995;63:369–377.CrossRefGoogle ScholarPubMed
243.Leuchter, AF, Morgan, M, Cook, IA, Dunkin, J, Abrams, M, Witte, E. Pretreatment neurophysiological and clinical characteristics of placebo responders in treatment trials for major depression. Psychopharmacology (Berl). 2004;177:15–22.CrossRefGoogle ScholarPubMed
244.Williams, LM, Gatt, JM, Hatch, A, et al.The INTEGRATE model of emotion, thinking and self regulation: an application to the “Paradox of Aging.” J Integr Neurosci. 2008;7:367–404.CrossRefGoogle Scholar
245.Williams, LM, Phillips, ML, Brammer, MJ, et al.Arousal dissociates amygdala and hippocampal fear responses: evidence from simultaneous fMRI and skin conductance recording. Neuroimage. 2001;14:1070–1079.CrossRefGoogle ScholarPubMed
246.Sartorius, N, Ustun, TB, Lecrubier, Y, Wittchen, HU. Depression comorbid with anxiety: results from the WHO study on psychological disorders in primary health care. Br J Psychiatry Suppl. 1996:38–43.Google Scholar
247.Hariri, AR, Lewis, DA. Genetics and the future of clinical psychiatry. Am J Psychiatry. 2006;163:1676–1678.CrossRefGoogle ScholarPubMed
248.Hariri, AR, Weinberger, DR. Imaging genomics. Br Med Bull. 2003;65:259–270.CrossRefGoogle ScholarPubMed
249.Hariri, AR, Mattay, VS, Tessitore, A, et al.Serotonin transporter genetic variation and the response of the human amygdala. Science. 2002;297:400–403.CrossRefGoogle ScholarPubMed
250.Pezawas, L, Meyer-Lindenberg, A, Drabant, EM, et al.5-HTTLPR polymorphism impacts human cingulateamygdala interactions: a genetic susceptibility mechanism for depression. Nat Neurosci. 2005;8:828–834.CrossRefGoogle Scholar
251.Hariri, AR, Drabant, EM, Munoz, KE, et al.A susceptibility gene for affective disorders and the response of the human amygdala. Arch Gen Psychiatry. 2005;62:146–152.CrossRefGoogle ScholarPubMed
252.Hong, CJ, Huo, SJ, Yen, FC, Tung, CL, Pan, GM, Tsai, SJ. Association study of a brain-derived neurotrophic-factor genetic polymorphism and mood disorders, age of onset and suicidal behavior. Neuropsychobiology. 2003;48:186–189.CrossRefGoogle ScholarPubMed
253.Oswald, P. Del-Favero, J, Massat, I, et al.No implication of brain-derived neurotrophic factor (BDNF) gene in unipolar affective disorder: evidence from Belgian first and replication patient-control studies. Eur Neuropsychopharmacol. 2005;15:491–495.CrossRefGoogle ScholarPubMed
254.Gatt, JM, Clark, CR, Kemp, AH, et al.A genotype-endophenotype-phenotype path model of depressed mood: integrating cognitive and emotional markers. J Integr Neurosci. 2007;6:75–104.CrossRefGoogle ScholarPubMed
255.Gatt, JM, Kuan, SA, Dobson-Stone, C, et al.Association between BDNF Val66Met polymorphism and trait depression is mediated via resting EEG alpha band activity. Biol Psychol. 2008;79:275–284.CrossRefGoogle ScholarPubMed
256.Gottesman, II, Gould, TD. The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry. 2003;160:636–645.CrossRefGoogle ScholarPubMed
257.Gould, TD, Gottesman, II. Psychiatric endophenotypes and the development of valid animal models. Genes Brain Behav. 2006;5:113–119.CrossRefGoogle ScholarPubMed
258.Corder, EH, Saunders, AM, Strittmatter, WJ, et al.Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261:921–923.CrossRefGoogle ScholarPubMed
259.Alexander, DM, Williams, LM, Gatt, JM, et al.The contribution of apolipoprotein E alleles on cognitive performance and dynamic neural activity over six decades. Biol Psychol. 2007;75:229–238.CrossRefGoogle ScholarPubMed
260.Egan, MF, Goldberg, TE, Kolachana, BS, et al.Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci U S A. 2001;98:6917–6922.CrossRefGoogle ScholarPubMed
261.Hariri, AR, Weinberger, DR. Functional neuroimaging of genetic variation in serotonergic neurotransmission. Genes Brain Behav. 2003;2:341–349.CrossRefGoogle ScholarPubMed
262.WMA. Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. October 2008. Available at: http://www.wma.net/e/policy/b3.htm. Accessed November, 2008.Google Scholar
263.Amsterdam, JD, Hornig, M, Nirenberg, AA. Treatment-Resistant Mood Disorders. Cambridge, UK: Cambridge University Press; 2001.CrossRefGoogle Scholar
264.Bagby, RM, Ryder, AG, Schuller, DR, Marshall, MB. The Hamilton Depression Rating Scale: has the gold standard become a lead weight? Am J Psychiatry. 2004;161:2163–2177.CrossRefGoogle ScholarPubMed
265.Hasler, G, Drevets, WC, Manji, HK, Charney, DS. Discovering endophenotypes for major depression. Neuropsychopharmacology. 2004;29:1765–1781.CrossRefGoogle ScholarPubMed
109
Cited by

Send article to Kindle

To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Improving the Prediction of Treatment Response in Depression: Integration of Clinical, Cognitive, Psychophysiological, Neuroimaging, and Genetic Measures
Available formats
×

Send article to Dropbox

To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

Improving the Prediction of Treatment Response in Depression: Integration of Clinical, Cognitive, Psychophysiological, Neuroimaging, and Genetic Measures
Available formats
×

Send article to Google Drive

To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

Improving the Prediction of Treatment Response in Depression: Integration of Clinical, Cognitive, Psychophysiological, Neuroimaging, and Genetic Measures
Available formats
×
×

Reply to: Submit a response

Please enter your response.

Your details

Please enter a valid email address.

Conflicting interests

Do you have any conflicting interests? *